Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Update

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,750,000 shares, an increase of 7.1% from the October 31st total of 3,500,000 shares. Based on an average daily volume of 336,300 shares, the short-interest ratio is presently 11.2 days. Approximately 14.5% of the company’s shares are sold short.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $4.35 on Tuesday. Inovio Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $14.75. The business has a 50-day moving average of $5.21 and a 200 day moving average of $7.56.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors have recently made changes to their positions in INO. BNP Paribas Financial Markets raised its stake in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Inovio Pharmaceuticals during the third quarter valued at $71,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $82,000. Signature Estate & Investment Advisors LLC bought a new position in Inovio Pharmaceuticals during the second quarter worth about $88,000. Finally, MetLife Investment Management LLC grew its position in Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 8,546 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

INO has been the topic of several recent research reports. Royal Bank of Canada decreased their target price on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. Oppenheimer lowered their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, November 18th. Finally, HC Wainwright dropped their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $38.00.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.